Associated British Foods Acquires Fytexia from ArchiMed

ARCHIMED-backed Fytexia Acquires B Natural

June 1, 2021

Food & Beverage

Fytexia, the ARCHIMED-owned health ingredients developer, has acquired Milan-based B Natural, a European leader in the extraction and refinement of propolis for health ingredients. The add-on strengthens Fytexia's product portfolio and R&D capabilities, expands its geographic reach, and is expected to boost group sales by about 40 percent.

ARCHIMED (via MED Platform I) Acquires Majority Stake in SUANFARMA

November 18, 2021

Pharmaceuticals

Transatlantic healthcare-focused private equity firm ARCHIMED, through its MED Platform I (MPI) fund, has acquired a majority stake in Madrid-based SUANFARMA, a manufacturer and distributor of active pharmaceutical ingredients (APIs) and nutraceutical ingredients. Ares Management provided debt financing for the transaction; SUANFARMA founder Héctor Ara and members of management rolled a material minority stake into the business and remain significant shareholders.

ARCHIMED Acquires Majority Stake in Germany's Zyto Group

January 12, 2021

Medical Devices

ARCHIMED, through its MED II fund, has acquired a majority stake in the Zyto group — a German developer, manufacturer and distributor of advanced cancer diagnostics, including Zytomed, ZytoVision and 42 Life Sciences. The deal will keep founders and management as significant minority shareholders and is intended to accelerate product innovation, regulatory capabilities and international expansion of the group's precision oncology diagnostics.

Nactarome Group Acquires Plantex SAS

October 16, 2025

Food & Beverage

Nactarome Group, majority owned by private equity firm TA Associates, has acquired Plantex SAS, a French producer of high-quality plant extracts for the food, nutraceutical, cosmetics and animal nutrition markets. The deal is an add-on to Nactarome’s ingredient platform to expand its plant-extraction capabilities and product offering; terms were not disclosed.

Aditxt, Inc. Acquires Evofem Biosciences, Inc.

December 12, 2023

Biotechnology

Aditxt, Inc. has entered into a definitive agreement to acquire Evofem Biosciences in a stock-and-debt assumption transaction that will make Evofem a wholly owned subsidiary of Aditxt pending closing (anticipated H1 2024). The deal transfers approximately $100 million of consideration via stock issuance and assumption of certain senior indebtedness, and positions Aditxt to establish a women's health mission and scale Evofem’s hormone-free contraceptive Phexxi and other women's health products globally.

ARCHIMED Acquires FIM Medical

October 15, 2024

Medical Devices

ARCHIMED, a healthcare-focused private equity firm, has acquired FIM Medical, a Lyon-based leader in occupational health medical devices specializing in vision testers, audiometers and spirometers. The acquisition, executed by ARCHIMED's MED Rise fund, positions the firm to strengthen its neuro & sensory and occupational health capabilities and support FIM Medical's international expansion.